The UNCOVER Study: From ICU to Long-Term Recovery - An International Cohort Study on Risk Factors, Trajectories, and Quality of Life in Sepsis Survivors
| Registry | NCT07863128, acronym UNCOVER |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Enrollment | 530 (Estimated) |
| Sponsor | University of Geneva, Switzerland (Other); collaborators: University of Zurich, University Health Network, Toronto, University of Sydney, European Society of Intensive Care Medicine, Università degli Studi di Trento, University Hospital, Geneva |
| Conditions | Sepsis, Long Term Care, Sepsis Scores, Long Term Follow-Up, Long Term Outcomes, PICS |
| Interventions | Care for Sepsis (Other) |
| Dates | start 2026-09-01, primary completion 2027-09-01 (estimated), completion 2028-09-01 (estimated), first posted 2026-10-07, last updated 2026-10-07 |
| Locations | 1 site in Switzerland |
Related Papers Related Patents Related Grants Related Experts
All trials for Sepsis All trials for Long Term Care All trials of Care for Sepsis
The goal of this observational study is to learn about the long-term outcomes and recovery of adult patients admitted to the intensive care unit (ICU) with sepsis.
The main questions it aims to answer are:
* Which patient-related, infection-related and centre-level factors (for example type of pathogen, time to adequate antibiotic therapy, and local sepsis management practices) are associated with poor quality of life six months after ICU admission for sepsis?
* How do these factors influence other patient-centred outcomes, such as mortality, psychological and cognitive recovery, functional status and return to work?
This is an international, multicentre, prospective observational cohort study. It will consecutively enrol adult patients (18 years or older) admitted to participating ICUs with sepsis, diagnosed by the treating clinician at ICU admission and, where locally available, meeting Sepsis-3 criteria.
Participants will:
* have clinical data collected from their medical records at ICU admission, on day 7 and at ICU discharge (infection characteristics, organ support, antibiotic therapy, delirium, rehabilitation and centre organisation);
* be followed at 28 days (medical record review, or telephone contact if already discharged) and contacted by telephone at 3 months and 6 months after ICU admission for structured assessment of quality of life, psychological and cognitive recovery, functional status, return to work and healthcare utilisation.
The study plans to enrol 600 patients in participating ICUs across several countries, coordinated by Geneva University Hospitals (HUG).
Findings will help identify modifiable factors that may improve long-term recovery and guide future interventions for sepsis survivors.
Sepsis is a leading cause of death and long-term disability worldwide. Survivors often experience persistent physical, psychological and cognitive impairments, described as Post-Sepsis Syndrome in addition to Post-Intensive Care Syndrome (PICS). Despite growing recognition of these complications, the factors influencing long-term outcomes - particularly the interaction between individual characteristics, infection-related factors and centre-level practices - remain poorly understood.
UNCOVER is a prospective, international, multicentre observational cohort study designed to investigate these associations in adult ICU patients with sepsis. Geneva University Hospitals (HUG) acts as the promoter. Participating centres enrol patients consecutively; each centre targets 30 consecutive patients during a six-month enrolment period, and enrolment stops once 600 participants have been included. Additional participating ICUs in Europe, the Americas, Asia-Pacific, the Middle East and Africa will be added to this record as local ethics approvals are obtained.
Data are collected from medical records at ICU admission, on day 7 and at ICU discharge, and at follow-up 28 days, 3 months and 6 months after ICU admission. Collected variables include:
* Centre-level data (collected once per centre): hospital and ICU admission rates, availability of infectious disease consultants and clinical pharmacists, physiotherapist-to-bed ratio, nurse-to-patient and doctor-to-patient ratios, junior/senior physician ratio, proportion of mechanical ventilation beds, existence of a local sepsis bundle, family visiting policy, open/closed ICU, public/private funding, university/non-university status, admissions and patient-days during the study period.
* Admission data: socio-demographics (age, sex, nationality, ethnicity, employment, financial status), APACHE II, SOFA, comorbidities (Charlson Comorbidity Index and individual comorbidities), Clinical Frailty Scale, CAM-ICU, Glasgow Coma Scale, baseline psychiatric comorbidity, code status (full code, DNR, DNI), intubation, vasopressors.
* Day 7 data: SOFA, GCS, delirium (CAM-ICU), cultures obtained and positive cultures with pathogen, resistance and antibiogram details, antibiotic adaptation, code status, intubation, vasopressors.
* ICU discharge data: source of infection, source control measures, time to adequate antibiotic therapy, type and duration of antibiotic therapy, new sepsis episodes during the ICU stay, imaging, mechanical ventilation and its duration, tracheostomy, new organ failures, dialysis, ECMO, delirium duration and treatment, caloric intake and deficit, thiamine and steroid administration, Barthel Index at ICU discharge.
* Environmental data: ICU diary, number of physiotherapy sessions per ICU length of stay, family presence at the bedside.
Because patients with sepsis are in an emergency situation and frequently lack decision-making capacity (altered consciousness, sedation, intubation), immediate inclusion with deferred consent is used, in accordance with articles 30 and 31 of the Swiss Human Research Act: advance directives are consulted, an independent physician not involved in the research safeguards the patient's interests, proxy consent is obtained from the legal representative or next of kin as soon as possible, and consent is requested from the patient post hoc as soon as capacity is recovered.
The primary outcome is health-related quality of life measured with the EQ-5D-5L at 6 months; poor quality of life is defined a priori as an EQ-5D-5L index value below 0.6. Secondary outcomes include 6-month mortality, broader quality of life (SF-12), cognitive function (T-MoCA), post-traumatic stress symptoms (IES-R), functional status (Barthel Index, extended Barthel, IADL), frailty (Clinical Frailty Scale), return to work and socio-economic recovery, rehospitalisation and healthcare utilisation, and patient-reported decision regret and preferences regarding future ICU admission.
Pre-specified secondary analyses will examine the association between long-term patient-centred outcomes and: sepsis-related delirium during the ICU stay; duration of antibiotic therapy (7 days or less versus more than 7 days); time to adequate antibiotic therapy; hospital-acquired versus community-acquired sepsis; immunosuppression; hyperoxia exposure during the ICU stay; and clinical parameters before initiation of renal replacement therapy as predictors of renal recovery and associated long-term quality of life.
The primary analysis uses a hierarchical logistic regression model with centre as a random intercept, with predictors at centre level (country), patient level (Clinical Frailty Scale, Charlson Comorbidity Index, SOFA) and infection level (time to adequate antibiotic therapy, source control achieved). Six-month mortality is analysed with a shared-frailty Cox model with centre as the frailty term. Analyses are performed in R (version 4.3 or higher) and STATA 16.1.
No experimental intervention is administered; all treatments follow local standard of care and remain the responsibility of the attending medical team. Data are coded at source and entered into a secure REDCap registry hosted by the Swiss Society of Intensive Care Medicine (SGI/SSMI).
The study is supported by a EUR 20,000 grant from the European Society of Intensive Care Medicine (ESICM), which has no role in the design, conduct, data collection, analysis, interpretation or decision to publish.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Sepsis Survivors Cohort | Other: Care for Sepsis | This cohort includes adult patients (≥18 years) admitted to participating intensive care units (ICUs) with a diagnosis of sepsis according to SEPSIS-3 criteria. Participants will be followed prospectively at 28 days, 3 months, and 6 months after ICU admission to assess patient-centered outcomes including quality of life, functional recovery, cognitive status, and mental health. No experimental interventions will be administered; all treatments follow standard clinical practice. Data on infection characteristics, antibiotic timing, and ICU management will be recorded for association analyses. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Adults aged 18 years or older * Sepsis (community- or hospital-acquired) diagnosed on ICU admission, defined as either: (a) a diagnosis of sepsis made by the treating clinician at ICU admission AND fulfilment of Sepsis-3 criteria; or (b) a diagnosis of sepsis made by the treating clinician at ICU admission alone, where Sepsis-3 criteria are not routinely available according to local protocol Exclusion Criteria: * Refusal to participate, by the patient or the legal representative * Inability to ensure follow-up (e.g. overseas residence, no fixed home address) * Sepsis acquired in the ICU * Patient admitted for palliative care
| Facility | City | Country | Status |
|---|---|---|---|
| Hopitaux Universitaires de Geneve (HUG) | Geneva | Switzerland | Recruiting |